Titan Medical files management information circular

Titan Medical announced the filing and mailing of its management information circular with respect to the amalgamation agreement with Conavi Medical providing for the combination of the companies in an all-stock transaction. This Transaction will constitute a reverse takeover of Titan. The Transaction was previously announced on March 17, 2024, with subsequent amendments to the Amalgamation Agreement announced on May 28, 2024, July 5, 2024 and August 14, 2024. The Circular provides detailed information on the expected benefits of the Transaction, terms and conditions, potential risks, voting procedures, and other relevant information. The Transaction is expected to provide meaningful benefits to Titan and its shareholders, including but not limited to: Ongoing Investment. Titan shareholders will be invested in a company with a growing market, a new technology that represents a compelling value proposition, and a strong and committed institutional investor base. Continuing Interest. Titan Shareholders will continue to hold a material interest in the entity resulting from the Transaction. Strong Incoming Team. The Resulting Issuer will have a strong leadership team with experience in capital markets and advanced medical devices. Concurrent Financing. As a closing condition to the Transaction, Conavi will be raising a minimum of $7.5 million in equity financing through a brokered private placement of subscription receipts which will provide growth capital to the merged company upon closing of the Transaction.